权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Vanderbilt Center for Diabetes Translation Research

范德比尔特糖尿病翻译研究中心

基本信息

批准号：
10016252
负责人：
TOM A ELASY
金额：
$ 66.19万
依托单位：
VANDERBILT UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10016252
关键词：
Academic Medical Centers Award Behavior Therapy Behavioral Caring Clinical Clinical Trials Collaborations Communities Community Health Community Outreach Development Diabetes Mellitus Diabetes prevention Direct Costs Doctor of Medicine Doctor of Philosophy Foundations Funding Goals Individual Institution Insulin-Dependent Diabetes Mellitus K-Series Research Career Programs Knowledge Lead Leadership Manuscripts Medial Methods Modification National Institute of Diabetes and Digestive and Kidney Diseases Non-Insulin-Dependent Diabetes Mellitus Obesity Publishing Research Research Personnel Risk Secure Services Structure Technology Translational Research Translations United States National Institutes of Health base cardiovascular risk factor college design diabetes control diabetes risk education research effective intervention ethnic minority population glycemic control health disparity high risk high risk population medical schools prevent programs racial minority success

项目摘要

Center Overview Project Summary/Abstract Clinical trials have established that glycemic control and cardiovascular risk factor modification can reduce the risk of complications of type 1 and type 2 diabetes. In addition, behavioral strategies have been shown to delay or prevent the development of type 2 diabetes in individuals at high risk for diabetes. Despite the clarity of evidence, many individuals with diabetes do not meet the recommended goals of diabetes care. There is an unequivocal gap between evidence and real-world diabetes prevention and treatment, and this gap is particular evident in many racial and ethnic minorities. Investigators at the Vanderbilt University Medical Center and Meharry Medical College propose a renewal to our Center for Diabetes Translation Research ( https://labnodes.vanderbilt.edu/cdtr ) to bridge this gap by building on our success in type II translation research. This renewal proposal is based on a highly productive initial five years and a plan for the next cycle that maintains continuity with our excellent leadership while introducing change to reflect the changing needs of our research base. During the past five years our research base has significantly enlarged (from 23 to 38), been well funded (annual direct costs from NIDDK alone of nearly five million), and published important manuscripts (136 cited). Our P&F program has been extremely successful (8 investigators funded for 30K/year for two years) in that four investigators have already received either a K award or a DP3 award and a fifth awardee has secured a RO1. We believe our P&F program, owing to the ability to leverage institutional matching funds and the ability to extend over two years, has been one of the most successful aspects of the Center. Our enrichment program is extensive and includes collaborations with multiple entities across campus. We propose to build on the excellence of the past five years by maintaining continuity in our core structure and leadership while introducing a new core (Behavioral Intervention Technologies and Services Core) and leader (Chandra Osborn, Ph.D.) to reflect the expanding research base that utilizes technology for behavioral interventions. We maintain a focus on health disparities through our long standing relationship with Meharry Medical College and build on that foundation by introducing a new leader (Consuelo Wilkins, M.D.) to lead our enrichment core. Dr. Wilkins leads the Meharry-Vanderbilt Alliance (https://medschool.vanderbilt.edu/meharry- vanderbilt/) which explicity promotes collaboration between our two institutions to promote clinical and community-engaged collaboration, education and research. These additions build on our theme of reducing health disparities while expanding on our efforts to advance knowledge in behavioral intervention technologies.

中心概况项目总结/摘要临床试验已经证实，血糖控制和心血管危险因素改变可以减少 1 型和 2 型糖尿病并发症的风险。此外，行为策略已被证明可以延迟或预防糖尿病高危人群患 2 型糖尿病。尽管清晰证据表明，许多糖尿病患者没有达到糖尿病护理的推荐目标。有一个证据与现实世界的糖尿病预防和治疗之间存在明确的差距，而且这种差距是特殊的在许多种族和少数民族中很明显。范德比尔特大学医学中心和梅哈里医学院的研究人员提议更新我们的糖尿病翻译研究中心（https://labnodes.vanderbilt.edu/cdtr）通过以下方式弥合这一差距：以我们在第二类翻译研究方面的成功为基础。该更新提案基于高效的最初的五年和下一个周期的计划，保持我们卓越领导力的连续性，同时引入变革以反映我们研究基地不断变化的需求。过去五年我们的研究基地显着扩大（从 23 个增加到 38 个），资金充足（仅 NIDDK 的年度直接费用近500万篇），发表重要手稿（被引136篇）。我们的 P&F 计划非常出色成功（8名研究人员每年获得3万美元资助，为期两年），因为4名研究人员已经收到 K 奖或 DP3 奖，第五位获奖者获得了 RO1。我们相信我们的 P&F 计划，由于能够利用机构配套资金并延长两年以上的能力，一直是其中之一该中心最成功的方面。我们的丰富计划内容广泛，包括合作与校园内的多个实体合作。我们建议通过保持核心结构的连续性和持续性来巩固过去五年的卓越表现领导力，同时引入新的核心（行为干预技术和服务核心）和领导者（钱德拉·奥斯本博士）反映了利用技术进行行为研究的不断扩大的研究基础干预措施。通过与梅哈里的长期合作关系，我们始终关注健康差异医学院并在此基础上引入一位新领导人（Consuelo Wilkins，医学博士）来领导我们的浓缩核心。威尔金斯博士领导梅哈里-范德比尔特联盟 (https://medschool.vanderbilt.edu/meharry- 范德比尔特/）明确促进我们两个机构之间的合作，以促进临床和社区参与的合作、教育和研究。这些新增内容建立在我们减少健康差异，同时扩大我们的努力，增进行为干预技术的知识。

项目成果

期刊论文数量（54）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Acceptability and Feasibility of FAMS-T1D mHealth intervention to optimize self- & social regulation for emerging adults with type 1 diabetes.

FAMS-T1D 移动健康干预措施优化自我的可接受性和可行性

DOI：
10.21203/rs.3.rs-2667134/v1
发表时间：
2023
期刊：
Research square
影响因子：
0
作者：
Mayberry,LindsayS;Wiebe,Deborah;Parks,Makenzie;Campbell,MaryJane;Beam,Aislinn;Berg,Cynthia
通讯作者：
Berg,Cynthia

Evaluating the brief health literacy screen--the authors' reply.

评估简短的健康素养筛查——作者的答复。